Synthesis and characterization of trastuzumab-Alexa 647 conjugate (HER-Alexa647)
Alexa 647-NHS ester was purchased from Thermo Fischer Scientific. Trastuzumab (0.2 mg, 1.36 nmol) and amine-reactive Alexa 647-NHS ester (antibody: dye mole ratio = 1:10) were simultaneously dissolved in 0.3 mL phosphate-buffered saline (PBS, pH 7.4, 10 mM, NaCl, 137 mM) at 25℃ and reacted for 1 h under light-protected conditions with gentle shaking. The unbound fluorophores and byproducts were removed from the mixture using a Sephadex G25 gel filtration column (PD-10; GE Healthcare, Little Chalfont, UK). Next, purified trastuzumab-fluorophore conjugates were concentrated using Amicon Ultra-0.5 mL centrifugal filters (membrane cut off: 50 K, EMD Millipore, Billerica, MA, USA) and stored at 4℃ for use as a stock solution.
The average number of Alexa 647 conjugated to trastuzumab (i.e., degree of labeling, DL) was determined by measuring the absorbance of trastuzumab-Alexa 647 conjugates in PBS using an UV/Vis spectrophotometer. The DL of the synthesized trastuzumab-Alexa 647
conjugates was calculated to be 3.63.
In vitro cell studies with HER-Alexa647
SK-BR-3 cells were plated at a density of 5 × 10 4 /well on a 4-well Lab-Tek II chambered coverglass and incubated overnight for cell attachment. Next, HER-Alexa 647 (10 µg/mL) was added to the medium and incubated for 30 min. Then, confocal fluorescence images (λex 633 nm, λem 647-754 nm) were acquired without washing the cells. The confocal images were analyzed using LSM 5 image browser, and profiling was conducted using Axiovision software (Carl Zeiss).
In vivo animal study with HER-Alexa647
All animal studies were approved by the Institutional Animal Care and Use Committee. 
